Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reata Hopes To Beat Competition To Market With Abbott Deals

This article was originally published in The Pink Sheet Daily

Executive Summary

Reata Pharmaceuticals hopes the strength of its partnerships and intellectual property will allow it to get an edge on a hot market.

Advertisement

Related Content

Abbott Spin-Off AbbVie To Remain Close To Its Roots
Abbott Pays $400 Million Upfront For Reata’s Preclinical AIM Programs
Reata Readies Bardoxolone For Phase III Looking At Kidney Function Outcomes
Reata Presents Bardoxolone Study Data That Spurred Abbott Deal
Reata's $450 Million Up-Front Haul Sets A Record But Remains An Outlier
Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073184

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel